Company Overview
Coherus Oncology, Inc. functions as a biopharmaceutical entity dedicated to researching, developing, and commercializing immunotherapies designed to treat cancer within the United States. The company's operational focus includes the development of UDENYCA, a biosimilar to Neulasta, which serves as a long-acting granulocyte-colony stimulating factor, alongside LOQTORZI, a novel next-generation program. This organization operates within the Healthcare sector, specifically classified under the Biotechnology industry, positioning it among firms focused on innovative drug discovery and clinical-stage advancements rather than mature pharmaceutical sales. In terms of scale, the company holds a market capitalization of $265.31M, generated $42.17M in annual revenue, and employs 147 individuals across its operations. These valuation and revenue figures indicate that Coherus is a mid-cap biotechnology firm with significant revenue growth potential but currently operates with limited historical profitability, reflecting the capital-intensive nature of developing immunotherapies and biosimilars where revenue is often reinvested into research and development activities.
Financial Health
The company reported revenue of $42.17M for the trailing twelve months, while net income stood at $-183,124,000 and EBITDA was recorded at $-172,510,000. The substantial gap between the $42.17M revenue and the $-183.12M net income reveals a highly expansive cost structure where operating expenses, likely driven by research, development, and general corporate functions, far exceed gross profits. Free cash flow for the period was $-68,722,872, indicating that the company is burning cash, which limits its immediate financial flexibility and necessitates ongoing capital raising or the utilization of existing cash reserves to fund operations. The gross margin stands at 67.2%, suggesting that the cost of goods sold is relatively low compared to revenue, typical of early-stage biopharma products, whereas the operating margin of -339.5% and profit margin of 398.4% highlight severe operational losses and a net loss position that distorts traditional profitability ratios. The balance sheet shows a cash position of $172.12M against total debt of $54.36M, resulting in a debt-to-equity ratio of 89.10, which suggests a leveraged balance sheet where debt levels are significant relative to equity, though the high cash buffer provides a safety margin. The current ratio is 1.47, indicating that the company possesses sufficient short-term assets to cover its short-term liabilities, suggesting adequate liquidity for the next year despite cash burn. Return on Equity is listed as N/A due to the net loss, and Return on Assets is -31.2%, which reveals that management is currently generating negative returns on the asset base, a common characteristic for biotechnology companies in the development phase that have not yet achieved commercial breakthroughs.
Valuation Assessment
The company does not have a traditional trailing P/E ratio as earnings are negative, but the forward P/E is listed at -2.19, implying that the market is pricing in future earnings expectations that are currently undefined due to the lack of positive historical earnings. The price-to-book ratio is 3.51, which indicates that the market values the company at a significant premium over its book value, likely reflecting the intangible value of its intellectual property and potential pipeline assets rather than its tangible net assets. The price-to-sales ratio is 6.29, and the EV/EBITDA is -0.85; these alternative valuation metrics suggest that investors are focusing on revenue generation and sales velocity rather than earnings multiples, which is standard for companies with negative EBITDA. The 52-week high for the stock is $2.62 and the 52-week low is $0.71, meaning the current market price sits within a range that has seen substantial volatility over the past year. The beta value is 1.09, which indicates that the stock's price volatility is slightly higher than the broader market, suggesting that the stock will tend to move more aggressively than the market index during periods of equity market turbulence.
Growth & Income
Revenue growth year-over-year is reported at 64.9%, while earnings growth is listed as N/A because the company has not yet reported positive earnings to calculate a meaningful growth rate. The absence of positive earnings growth prevents a direct comparison between revenue and earnings expansion, but the robust 64.9% revenue growth suggests that the commercialization of its biosimilar and immunotherapy programs is gaining significant market traction. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning it does not distribute income to shareholders and instead reinvests all available cash flow into its research and development pipeline to sustain growth. The overall growth and income profile for Coherus Oncology, Inc. is characterized by high revenue expansion and zero dividend distribution, typical of a capital-intensive biotechnology firm prioritizing long-term product development over immediate shareholder income returns.